Compugen (CGEN) Tops Q2 EPS by 1c

Go back to Compugen (CGEN) Tops Q2 EPS by 1c

Compugen Reports Second Quarter 2022 Results

August 4, 2022 7:00 AM EDT

Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902Focus on MSS-CRC and NSCLC expected to provide highest probability of success and support future path to registrationFocused development plan results in strategic decision to wind down Phase 1 cohort expansion studies resulting in the conclusion of collaboration with Bristol Myers SquibbMost advanced preclinical program with first-in-class potential entering pre-IND enabling studiesExtended cash runway expected to last through the end of 2024

HOLON, Israel, Aug. 4, 2022 /PRNewswire/ --... More